Results 21 to 30 of about 277,018 (298)

Kernel Logistic Regression-linear for Leukemia Classification Using High Dimensional Data [PDF]

open access: yes, 2009
Kernel Logistic Regression (KLR) is one of the statistical models that has been proposed for classification in the machine learning and data mining communities, and also one of the effective methodologies in the kernel–machine techniques.
Rahayu, S. P. (S)   +3 more
core   +2 more sources

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition

open access: yesHaematologica, 2020
MCL-1 and BCL-2 are both frequently overexpressed in acute myeloid leukemia (AML) and critical for the survival of AML cells and AML stem cells. MCL-1 is a key factor in venetoclax resistance.
Bing Z. Carter   +10 more
doaj   +1 more source

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia

open access: yesScientific Reports, 2021
Peposertib (M3814) is a potent and selective DNA-PK inhibitor in early clinical development. It effectively blocks non-homologous end-joining repair of DNA double-strand breaks (DSB) and strongly potentiates the antitumor effect of ionizing radiation (IR)
Eric Haines   +9 more
doaj   +1 more source

Detection of monosomy 7 in interphase cells of patients with myeloid disorders [PDF]

open access: yes, 1990
Six patients, five with acute myeloid leukemia (AML) and one with a myelodysplastic syndrome (MDS), were found to have monosomy 7 by conventional cytogenetics at diagnosis.
Cremer, Thomas   +5 more
core   +1 more source

Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model

open access: yesHaematologica, 2020
Although highly effective, BCR-ABL1 tyrosine kinase inhibitors do not target chronic myeloid leukemia (CML) stem cells. Most patients relapse upon tyrosine kinase inhibitor therapy cessation.
Bing Z. Carter   +10 more
doaj   +1 more source

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models

open access: yesFrontiers in Immunology, 2022
Immunotherapy with T-cells expressing bispecific T-cell engagers (ENG T-cells) is a promising approach to improve the outcomes for patients with recurrent/refractory acute myeloid leukemia (AML).
Hong Mu-Mosley   +7 more
doaj   +1 more source

Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival

open access: yesHaematologica, 2018
Mesenchymal stromal cells (MSC) support acute myeloid leukemia (AML) cell survival in the bone marrow (BM) microenvironment. Protein expression profiles of AML-derived MSC are unknown.
Steven M. Kornblau   +16 more
doaj   +1 more source

Superoxide Dismutase and Vitamin E Levels in Serum as Indicators in Patients with Acute and Chronic Leukemia [PDF]

open access: yesJournal of Applied Sciences and Nanotechnology, 2022
Oxidative stress has been linked to the development of a variety of malignancies, including leukemia. Furthermore, the incidence of leukemia increases with age due to an increase in the number of free radicals reacting with age and a lower ability of the
Reem Al-Qaisi   +2 more
doaj   +1 more source

Detection of t(7;12)(q36;p13) in paediatric leukaemia using dual colour fluorescence in situ hybridisation [PDF]

open access: yes, 2015
The identification of chromosomal rearrangements is of utmost importance for the diagnosis and classification of specific leukaemia subtypes and therefore has an impact on therapy choices in individual cases.
Federico, C   +4 more
core   +2 more sources

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

open access: yesHaematologica, 2018
Targeted therapies against FLT3-mutated acute myeloid leukemias have shown limited clinical efficacy primarily because of the acquisition of secondary mutations in FLT3 and persistent activation of downstream pro-survival pathways such as MEK/ERK, PI3K ...
Weiguo Zhang   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy